TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01434069
Drug: SOM230C LAR
Normalized name: pasireotide
DrugBank: Pasireotide (DB06663)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be given one LAR dose injected into the muscle of the buttocks by a study nurse about once every 28 days until unacceptable toxicity or progression of the disease.
Study: NCT02246764
Drug: Timolol maleate Ophthalmic Solution 0.5% BID
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 drop BID, AM/PM, OU
Study: NCT01434069
Drug: FOLFIRI Infusion
Normalized name: Duo Fusion
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard therapy of FOLFIRI
Study: NCT02335294
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rescue: Ibuprofen, oxycodone
Study: NCT00403949
Drug: Azelaic acid 15% gel
Normalized name: AZELAIC ACID 15% GEL,TOP
DrugBank: Azelaic acid (DB00548)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: gel, applied once daily, for 6 weeks
Study: NCT00403949
Drug: Non-active base from azelaic acid 15% gel
DrugBank: Azelaic acid (DB00548)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: gel, apply once daily for six weeks
Study: NCT03164837
Drug: 68Ga-NOTA-RM26
Normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose 68Ga-NOTA-RM26 were injected into the patients before the PET/CT scans.
Study: NCT03201978
Drug: GSK2894512 MATCHING VEHICLE CREAM
Normalized name: ACh
DrugBank: Acetylcholine (DB03128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: It will be prepared as close as possible to the time of administration to avoid a prolonged exposure to light. Each single cream application will be made by weight, dispensed on hand (fingertips) covered with clean disposable glove and evenly spread using fingertips.
Study: NCT04244006
Drug: Dupilumab Prefilled Syringe
Normalized name: dupilumab Prefilled Syringe
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: administration of dupilumab corresponding to dupilumab arm
Study: NCT03657238
Drug: RD01
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: single S.C. dose of RD01 for subjects in test group
Study: NCT00426530
Drug: everolimus (RAD001)
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00894842
Drug: Pregnenolone
Normalized name: Pregnenolone
DrugBank: Pregnenolone (DB02789)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregnenolone 50 mg BID x 14 days, followed by Pregnenolone 300 mg per day for 14 days (200 mg qAM and 100 mg qPM), followed by Pregnenolone 500 mg per day for the remainder of the 8-week trial (300 mg qAM and 200 mg qPM)
Study: NCT00458419
Drug: naloxone versus placebo
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg of naloxone administered IV or normal saline administered IV in randomized order at different visits
Study: NCT00458419
Drug: intravenous injection of normal saline or naloxone
Normalized name: Rosula NS Medicated Pad or Tape
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arm A: 10 mg of naloxone given IV in 25 ml of normal saline Arm B: 25 ml of normal saline
Study: NCT02347319
Drug: Pennel
Normalized name: Fennel
DrugBank: Fennel (DB15615)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pennel 2 Tablet, Legalon Placebo 1 tablet, Tid
Study: NCT02347319
Drug: Legalon
DrugBank: Silibinin (DB09298)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pennel Placebo 2 Tablet, Legalon 1 tablet, Tid
Study: NCT03844997
Drug: Palcociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palbociclib is an investigational (experimental) drug that works to induce early G1 arrest by inhibiting CDK4/6, which are two types of CDKs that are overexpressed in AML cell cancer lines. Palbociclib is experimental because it is not approved by the Food and Drug Administration (FDA).~Palbociclib will be supplied as capsules or tablets containing 125 mg equivalents of Palbociclib free base
Study: NCT03844997
Drug: CPX-351
Normalized name: CPX
DrugBank: DPCPX (DB12946)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPX-351 (daunorubicin and cytarabine) liposome for injection is a combination of daunorubicin and cytarabine in a 1:5 molar ratio encapsulated in liposomes for intravenous administration. CPX-351 is an investigational (experimental) drug that works as formulation of a fixed combination of the antineoplastic drugs cytarabine and daunorubicin. CPX-351 is experimental because it is not approved by the Food and Drug Administration (FDA).
Study: NCT01454440
Drug: Eptifibatide
Normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous eptifibatide (double bolus \[180 microg/kg\] followed by infusion \[2 microg/kg per minute\] for 18 to 24 hours after the procedure) vs placebo.
Study: NCT03843515
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Neoadjuvant nivolumab flat dose 400mg
Study: NCT00757549
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00850681
Drug: PEP005 (ingenol mebutate) Gel
Normalized name: Ingenol Mebutate Topical Gel
DrugBank: Ingenol mebutate (DB05013)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PEP005 (ingenol mebutate) Gel, 0.01%
Study: NCT02079675
Drug: SKI3246 Low Dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: SKI3246 Low Dose will be taken for a 4-week duration (28 days) as 4 capsules a day: two capsules in the morning and two capsule in the evening
Study: NCT02079675
Drug: SKI3246 High Dose
Normalized name: HIGH DENSITY POLYETHYLENE
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SKI3246 High Dose will be taken for a 4-week duration (28 days) as 4 capsules a day: two capsules in the morning and two capsule in the evening
Study: NCT04429867
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine 400 mg PO BID x 2 doses, then 200 mg PO BID x 8 doses
Study: NCT01122316
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 3. Metformin will be started at 500 mg PO BID and pending lab values may be titrated to 1000 mg PO BID at 1 month.
Study: NCT00367016
Drug: Omalizumab
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Xolair (Omalizumab) will be given by subcutaneous injection according to Ige level and weight calculation.
Study: NCT02988882
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03110380
Drug: F/TAF
Normalized name: Emtricitabine/Tenofovir Alafenamide
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200/25 mg FDC tablet(s) administered orally once daily
Study: NCT03110380
Drug: DTG
Normalized name: Dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg tablet(s) administered orally once daily
Study: NCT01011556
Drug: Subcutaneous Teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered subcutaneously once daily for 12 months
Study: NCT01011556
Drug: Transdermal Teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered transdermally, applied once daily for 6 hours over 12 months
Study: NCT03318887
Drug: Sofosbuvir/daclatasvir with or without ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Direct-acting antiviral treatment for hepatitis C virus infection
Study: NCT00869661
Drug: Copegus
Normalized name: Copegus
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000/1200mg po daily for 24 or 48 weeks
Study: NCT00869661
Drug: Copegus
Normalized name: Copegus
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000/1200mg po daily for 48 weeks
Study: NCT00869661
Drug: Pegasys
Normalized name: Pegasys
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 180 micrograms sc weekly for 24 or 48 weeks
Study: NCT00869661
Drug: Pegasys
Normalized name: Pegasys
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 180 micrograms sc weekly for 48 weeks
Study: NCT01908205
Drug: Intranasal Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00640458
Drug: Sildenafil 100 mg
Normalized name: sildenafil 100 MG
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01501968
Drug: Colistin
Normalized name: Colistin
DrugBank: Colistin (DB00803)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colistimethate sodium 2.5-5mg/kg iv per day
Study: NCT01355302
Drug: E7050
Normalized name: Elafibranor
DrugBank: Elafibranor (DB05187)
Approvals — FDA: no, EMA: no, PMDA: no
Description: E7050 given orally at either 200, 300, or 400 mg once daily.
Study: NCT01355302
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin will be administered at 80 mg/m2 by intravenous infusion over 60 minutes on Day 1 of each 21-day treatment cycle.
Study: NCT01712451
Drug: salmeterol xinafoate, fluticasone propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: LIPO-102
Study: NCT01712451
Drug: salmeterol xinafoate
Normalized name: Salmeterol Xinafoate
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Salmeterol
Study: NCT02091310
Drug: Moxifloxacin 400 mg
Normalized name: moxifloxacin 400 MG
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00560326
Drug: Tacrolimus Ointment 0.03%
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once or twice daily topical application
Study: NCT05025631
Drug: Fruquintinib
Normalized name: fruquintinib
DrugBank: Fruquintinib (DB11679)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruquintinib was administered for 21 consecutive days of a 28-day treatment cycle. The starting dose of fruquintinib was 3 mg/day, weekly incremental dose escalation occurred up to the maximum of 5 mg/day if no significant drug-related toxicities were observed. The highest tolerated dose from cycle 1 would be administered in cycle 2 and all subsequent cycles.
Study: NCT03847974
Drug: LIB003
Normalized name: Protein lib003 (recombinant human proprotein convertase subtilisin/kexin type 9 ligand-binding tenth fibronectin type iii domain) fusion protein with peptide (synthetic 6-amino acid linker) fusion protein with serum albumin (34-alanine) (human)
DrugBank: Lerodalcibep (DB19071)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg SC Q4W
Study: NCT00838981
Drug: Modafinil
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Modafinil is started at 200mg on the first day of week 1 (treatment phase) and increased to 400mg by the end of that week. Subjects will continue to receive 400mg/day for the remainder of the study.
Study: NCT00838981
Drug: Sugar Pill
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo, sugar pill will mirror active drug
Study: NCT00838981
Drug: Methadone
Normalized name: Methadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be started on 30 mg of methadone and the dose will be increased as tolerated to reach 60 mg at the end of the first 1-2 weeks of the induction phase. Methadone dosing will bestabilized. During methadone maintenance (weeks 1-11 of treatment phase), subjects continue to receive their maintenance doses of methadone plus modafinil or placebo.
Study: NCT00490854
Drug: Neutral protamine hagedorn insulin
Normalized name: Neutral protamine hagedorn insulin
DrugBank: Neutral Protamine Hagedorn (NPH) insulin (DB18001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: patient specific dose, injected, daily, 76 weeks
Study: NCT04385095
Drug: SNG001
Normalized name: SNG001
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SNG001 via inhalation
Study: NCT01283646
Drug: Vitamin B Complex + Vitamin C
Normalized name: vitamin B complex
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3.5 to 5 ml 3 times a daily
Study: NCT00754871
Drug: Dienogest (81150037)
Normalized name: Dienogest
DrugBank: Dienogest (DB09123)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: daily oral intake of 0.5 mg dienogest over two cycles or a max. of 72 days
Study: NCT00754871
Drug: Dienogest (81150231)
Normalized name: Dienogest
DrugBank: Dienogest (DB09123)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: daily oral intake of 1.0 mg dienogest over two cycles or a max. of 72 days
Study: NCT00754871
Drug: Dienogest (SH T00660A)
Normalized name: Dienogest
DrugBank: Dienogest (DB09123)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: daily oral intake of 2.0 mg dienogest over two cycles or a max. of 72 days
Study: NCT00754871
Drug: Dienogest (81150746)
Normalized name: Dienogest
DrugBank: Dienogest (DB09123)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: daily oral intake of 3.0 mg dienogest over two cycles or a max. of 72 days
Study: NCT02802215
Drug: metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin group will receive 1500 mg of metformin per day orally ( 500 mg every 8hrs in the middle of meal) starting from 12th week of gestation till delivery.
Study: NCT00587431
Drug: GnRh (Leuprolide)
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leuprolide LUPRON
Study: NCT00587431
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 70 mg/m2 given on day o1 of each 3 week cycle
Study: NCT00197080
Drug: Ropinirole Extended Release (XR)
Normalized name: ropinirole Extended Release Oral Tablet
DrugBank: Ropinirole (DB00268)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00116480
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 600 mcg of sublingual misoprostol
Study: NCT00375791
Drug: perifosine
Normalized name: Perifosine
DrugBank: Perifosine (DB06641)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 - 150 mg daily
Study: NCT00375791
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 mg twice weekly
Study: NCT00732524
Drug: Glipizide
Normalized name: Glipizide
DrugBank: Glipizide (DB01067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glipizide XL 10 mg once daily 30 mins before breakfast
Study: NCT00732524
Drug: Glipizide and Glargine
Normalized name: insulin glargine and lixisenatide
DrugBank: Glipizide (DB01067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glipizide XL 10 mg daily 30 minutes before breakfast Insulin Glargine 10 units subcutaneously at bedtime daily
Study: NCT01287455
Drug: Vitamin D3 as BABY D3
Normalized name: vitamin D3
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: drops, 70 drops (= 14000 units), once weekly for 6 weeks
Study: NCT02015169
Drug: Lapatinib
Normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: lapatinib 1250mg qd daily up to 8 cycles (3 weeks \* 8 cycles = 24 weeks)
Study: NCT00120315
Drug: esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: esomeprazole, original Nexium, 40 mg pills Up to once a day
Study: NCT00779220
Drug: ocrelizumabu 50mg
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous repeating dose (50mg)
Study: NCT00779220
Drug: ocrelizumabu 200mg
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous repeating dose (200mg)
Study: NCT00779220
Drug: ocrelizumab 500mg
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous repeating dose (500mg)
Study: NCT02762994
Drug: BCD-085
Normalized name: anacaulase-bcdb
DrugBank: Anacaulase (DB17449)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04347330
Drug: Intensive BP Control
Normalized name: Uricalm Intensive
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants in the Intensive group have a goal of home SBP \<120 mm Hg. The CRAFT BP treatment protocol is flexible in terms of the choice and doses of antihypertensive medications, but there should be preferences among the drug classes, based on CVD outcome trials results and current guidelines. Use of once-daily antihypertensive agents will be encouraged unless alternative frequency is indicated/necessary. Combination of different classes of agents are encouraged to achieve the home SBP goal. Medications will not be provided by the CRAFT study.
Study: NCT01836614
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The treatment group will receive a 1.5mg/kg intravenous lidocaine bolus over 10 minutes after induction by means of an infusion pump. This bolus will be followed by an intravenous lidocaine infusion of 1 mg/kg/hr. The infusion will be stopped after extubation prior to leaving the operative room or after 5 hours from the start of the infusion, which ever comes first.
Study: NCT00980408
Drug: Sugar pill
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg, one dose, 60 min prior
Study: NCT00980408
Drug: Sugar pill
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg, one dose, 8 hours prior
Study: NCT00980408
Drug: Memantine
Normalized name: Memantine
DrugBank: Memantine (DB01043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg, one dose, 8 hours prior
Study: NCT03380130
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: An anti-programmed death 1 monoclonal antibody
Study: NCT03721627
Drug: Ledipasvir/Sofosbuvir
Normalized name: LEDIPASVIR/SOFOSBUVIR
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Direct acting anti HCV drugs
Study: NCT00136760
Drug: Bupropion
Normalized name: Bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Contingent reinforcement plus bupropion (300 mg/day for 3 weeks)
Study: NCT00136760
Drug: non-contingent reinforcement plus bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: non-contingent reinforcement plus bupropion (300 mg/day for 3 weeks)
Study: NCT02226991
Drug: Tipranavir
Normalized name: Tipranavir
DrugBank: Tipranavir (DB00932)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02226991
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02226991
Drug: Efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00330460
Drug: Alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ALN; 70 mg; oral; once weekly
Study: NCT00330460
Drug: Denosumab
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 60 mg; SC; every 6 months
Study: NCT01634412
Drug: Cyclobenzaprine Tablet
Normalized name: cyclobenzaprine Oral Tablet
DrugBank: Cyclobenzaprine (DB00924)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 x 5 mg cyclobenzaprine tablet, swallowed with 240 mL of room-temperature water
Study: NCT01634412
Drug: Cyclobenzaprine IV
DrugBank: Cyclobenzaprine (DB00924)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 dose of 2.4 mg cyclobenzaprine USP in PBS (0.6 mg/mL) at pH 7.4, administered intravenously as a 4 mL bolus injection over 30 seconds
Study: NCT01446224
Drug: Pazopanib
Normalized name: Pazopanib
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients treated with pazopanib
Study: NCT00159536
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin 1000 mg x 2 per day. Orally. From inclusion (before gestational week 12) to delivery. Verbal and written diet and lifestyle advices at inclusion to the study
Study: NCT01446224
Drug: Other anti-VEGFs
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients treated with other anti-VEGFs including Bevacizumab, Sorafenib, and Sunitinib
Study: NCT01332721
Drug: TRC105 and Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Escalating doses of i.v. TRC105 will be administered weekly beginning with 3 mg/kg in combination with 15 mg/kg bevacizumab given every 3 weeks. Patients will receive TRC105 treatment on Days 1, 8, and 15 and bevacizumab treatment on Day 1 of each 21-day cycle.
Study: NCT04689893
Drug: 68Ga-Dotatate
Normalized name: 68Ga-DOTATATE
DrugBank: Dotatate gallium Ga-68 (DB13925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 68Ga-Dotatate was injected into the patients before the PET/CT scans
Study: NCT04689893
Drug: 68Ga-DOTA-JR11
Normalized name: 68Ga-DOTATATE
DrugBank: Dotatate gallium Ga-68 (DB13925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 68Ga-DOTA-JR11 was injected into the patients before the PET/CT scans
Study: NCT01290237
Drug: vancomycin hydrocloride
Normalized name: Vancomycin Hydrochloride
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: see description of study arms
Study: NCT00329628
Drug: Rivaroxaban (BAY59-7939)
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10 mg OD tablet of rivaroxaban administered for 36 +/- 4 days
Study: NCT00329628
Drug: Enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syringe of Enoxaparin active substance at a dose of 40 mg administered for 13 +/- 2 days
Study: NCT02635035
Drug: Lisdexamfetamine
Normalized name: Lisdexamfetamine
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Vyvanse (Lisdexamfetamine Dimesylate) manufactured by Shire, is a Drug Enforcement Administration (DEA) class two,sympathomimetic amine, used for the treatment of attention-deficit hyperactivity disorder. The initial adult dosage is 30mg with allowed adjustments in increments of 10mg or 20mg at weekly intervals. Subjects are initiated on these doses and then they were titrated up by 20mg with a maximum dose of 70mg.